Statin-Induced Myopathy: Translational Studies from Preclinical to Clinical Evidence.

Abstract

Statins are the most prescribed and effective drugs to treat cardiovascular diseases (CVD). Nevertheless, these drugs can be responsible for skeletal muscle toxicity which leads to reduced compliance. The discontinuation of therapy increases the incidence of CVD. Thus, it is essential to assess the risk. In fact, many studies have been performed at preclinical and clinical level to investigate pathophysiological mechanisms and clinical implications of statin myotoxicity. Consequently, new toxicological aspects and new biomarkers have arisen. Indeed, these drugs may affect gene transcription and ion transport and contribute to muscle function impairment. Identifying a marker of toxicity is important to prevent or to cure statin induced myopathy while assuring the right therapy for hypercholesterolemia and counteracting CVD. In this review we focused on the mechanisms of muscle damage discovered in preclinical and clinical studies and highlighted the pathological situations in which statin therapy should be avoided. In this context, preventive or substitutive therapies should also be evaluated.

• Authors: Giulia Maria Camerino, Nancy Tarantino, Ileana Canfora, Michela De Bellis, Olimpia Musumeci, Sabata Pierno
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 22 Issue 4 (Feb 19 2021) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 33669797 (Publication Type: Journal Article, Review)

Chemical References

• Biomarkers
• Hydroxymethylglutaryl-CoA Reductase Inhibitors

Topics

• Animals
• Biomarkers (metabolism)
• Drug Interactions
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (adverse effects)
• Muscular Diseases (chemically induced, genetics)
• Risk Factors
• Translational Research, Biomedical